AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), today announced the closing of its $63 million Series B2 financing.
The financing was strongly supported by the company’s existing syndicate of investors, underscoring confidence in AusperBio’s breakthrough approach to achieving a functional cure for CHB. The round was co-led by Qiming Venture Partners and a globally renowned strategic investor, with continued participation from HanKang Capital, CDH Investments, YuanBio Venture Capital, Sherpa Capital, and Genesis Capital.
Proceeds from the financing will be used to advance the clinical development of AHB-137, AusperBio’s lead product candidate, including the ongoing pivotal trial, multiple Phase II combination studies, and expansion into global Phase II development. The funds will also support further advancement of the company’s proprietary Med-Oligo™ ASO platform, progression of its preclinical pipeline, scaling-up of commercial manufacturing partnerships, and long-term pipeline growth.
Dr. Guofeng Cheng, co-founder and CEO of AusperBio, commented, “We are grateful for the continued support of our investors, whose confidence reflects both the progress of our clinical programs and the promise of our Med-Oligo™ platform. This financing positions us to accelerate the pivotal development of AHB-137, expand our global clinical footprint, strengthen our platform and pipeline, and advance our long-term vision of delivering a functional cure for people living with chronic hepatitis B and beyond.”
Dr. Chris Yang, co-founder and CSO of AusperBio, added, “AHB-137 is the first candidate from our Med-Oligo™ platform to reach pivotal development, and the data reinforce its potential as a backbone therapy for CHB. This financing will accelerate the development of our next generation combination therapy for CHB and support continued advancement of a pipeline of innovative targeted oligonucleotide therapeutics addressing a broad range of diseases with serious unmet medical need.”
